阿斯利康AstraZeneca plc (AZN) 2015年年度报告「LSE」.pdf

1、What science can doAstraZeneca Annual Report and Form 20-F Information 2015Learn about our main therapy areas:Welcome to the AstraZeneca Annual Report and Form 20-F Information 2015.We are a global,science-led biopharmaceutical business and in this Annual Report we report on the progress we made in

2、2015 in pushing the boundaries of science to deliver life-changing medicines.AstraZeneca.What science can do.Respiratory,Inflammation and AutoimmunityWe have pushed the boundaries of science in respiratory disease for 40 years See page 26Cardiovascular and Metabolic diseasesWe take an integrated pat

3、ient approach to reduce cardiovascular morbidity and mortality See page 30OncologyWe are committed to advancing the science of oncology See page 34Pushing the boundaries Breaking through conventional thinking Redefining the treatment paradigmFrom page 4,Pascal Soriot,our Chief Executive Officer,revi

4、ews the progress we made during the year in delivering our strategy.Our Chief Financial Officer,Marc Dunoyer,reviews our financial performance from page 62.From page 82,Leif Johansson,our Chairman,reviews how our governance and approach to remuneration support delivery of the strategy.Important info

5、rmation for readers of this Annual Report For more information in relation to the inclusion of reported performance,Core financial measures and constant exchange rate(CER)growth rates as used in this Annual Report,please see the Financial Review on page 64.Throughout this Annual Report,growth rates

6、are expressed at CER unless otherwise stated.DefinitionsThe Glossary and the Market definitions table from page 247 are intended to provide a useful guide to terms and AstraZenecas definitions of markets,as well as to acronyms and abbreviations,used in this Annual Report.Use of terms In this Annual